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The advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors
(TKIs) has considerably transformed the therapeutic management of a subset of patients
with non-small-cell lung cancer (NSCLC) harboring defined molecular abnormalities. When
such genetic molecular alterations are detected the use of specific TKI has demonstrated
better results (overall response rate, progression free survival) compared to systemic ther-
apy. However, the detection of such molecular abnormalities is complicated by the difficulty
in obtaining sufficient tumor material, in terms of quantity and quality, from a biopsy. Here,
we described how circulating tumor cells (CTCs) can have a clinical utility in anaplastic
lymphoma kinase (ALK ) positive NSCLC patients to diagnose ALK-EML4 gene rearrange-
ment and to guide therapeutic management of these patients.The ability to detect genetic
abnormalities such ALK rearrangement in CTCs shows that these cells could offer new
perspectives both for the diagnosis and the monitoring of ALK -positive patients eligible for
treatment with ALK inhibitors.
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In the past decade, the treatment of non-small-cell lung cancer
(NSCLC) has considerably shifted with the emergence of rationally
targeted therapies for a subset of molecularly defined lung cancers.
NSCLCs and in particular adenocarcinoma, the most frequent
histologic subtype, have been segmented into clinically relevant
molecular subsets according to a classification based on multi-
ple so-called oncogenic “driver” alterations (Figure 1A) (1). These
somatic aberrations occur in genes that encode signaling proteins
crucial for tumor proliferation and survival. Tumors harboring
these mutant oncogenes may be systematically identified and tar-
geted specifically using tyrosine kinase inhibitor (TKI) therapies
that ensure dramatic and durable clinical benefit. The first example
of a clinically relevant NSCLC driver oncogene was the identifica-
tion of somatic mutations in the epidermal growth factor receptor
(EGFR) gene (2–4).Common EGFR alterations (the L858R point
mutation and exon 19 deletions) are present in 10–30% of patients
with NSCLC and confer sensitivity to gefitinib, erlotinib, and afa-
tinib. As first-line treatment, EGFR inhibitors can produce overall
response rates (ORR) of 75% in selected NSCLC patients (5).
Similarly to EGFR mutations, the ALK -gene rearrangement
defines a unique molecular subset in 3–7% of NSCLC patients
(6). ALK -gene rearrangement involves the anaplastic lymphoma
kinase (ALK ) gene and, most often, the echinoderm microtubule-
associated protein-like 4 (EML4) loci which both map to the
short arm of the human chromosome 2 in opposite directions
(7, 8) (Figure 1B). Several different in-frame fusion variants of
EML4-ALK have been described with differentEML4 breakpoints.
However, all fusion variants contain the same C-terminal domain,
which confers a gain of function resulting in constitutively active
fusion proteins with potent transforming activity. The clinical
characteristics of NSCLC patients that are positive for EML4-ALK
variants are similar to those of who harbor activating mutations
in the EGFR gene: both groups of patients tend to manifest an
adenocarcinoma histological subtype and to be non or light smok-
ers (9). The discovery that the EML4-ALK fusion protein was a
potent oncogenic driver in NSCLC rapidly fueled the develop-
ment of the multi-targeted TKI crizotinib, and accelerated its FDA
approval for the treatment of patients with advancedALK -positive
NSCLC. Two studies have since shown an ORR of 60% and a
median progression free survival (PFS) of 8–9 months in ALK -
positive NSCLC patients receiving crizotinib (10). Another study
compared treatment with crizotinib to chemotherapy in ALK-
positive NSCLC patients and showed that the PFS was longer for
patients receiving crizotinib (7.7 months) than for those treated
with chemotherapy (3 months) (11). Despite this high response
rate in ALK -rearranged NSCLC, most patients develop resis-
tance to crizotinib, typically within 1 year. Next generation ALK
inhibitors with potentially improved efficacy and selectivity com-
pared to crizotinib are currently being developed to overcome this
resistance to crizotinib. In a recent phase I study, ceritinib demon-
strated marked anti-tumor activity in both crizotinib-relapsed and
crizotinib-naive patients (12).
Prospective molecular profiling of NSCLC is now performed
in routine clinical practice to identify oncogenic “driver” abnor-
malities and to screen eligible patients for targeted TKI therapies.
Tumor tissue may be difficult to obtain in advanced/metastatic
NSCLC patients for whom surgery is rarely a component of the
treatment strategy. The molecular characteristics or biomarkers
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FIGURE 1 | Molecular characterization of CTC inALK -rearranged
non-small-cell lung cancer. (A) Pie chart of NSCLC mutations and
scheme representation of ALK rearrangement. Percentage of known
somatic mutations in oncogenic drivers in NSCLC. Pie chart of NSCLC
mutations. (B) Scheme of EML4-ALK rearrangement. The two genes are
located on chromosome 2 in position 2p21 and 2p23, respectively for
EML4 and ALK. The rearrangement is the result of a chromosomal
inversion. (C) Examples of ALK -gene abnormalities detected by FA-FISH.
ALK -rearranged CTC with an ALK native copy (yellow signal) and an
ALK-rearranged copy. Arrows show the ALK rearrangement with a split
3′ and 5′ (red/green) signal (left). ALK -rearranged CTC with a gain of
native ALK copies (yellow signals) and an ALK -rearranged copy as
shown in (A) and indicated by arrows (middle). CTC with a gain of ALK
native copies (right). (D) Example of ALK-rearranged mesenchymal CTC.
Immunofluorescence staining (Hoechst/Vimentin) and ALK -rearranged
CTC with gain of ALK native copy (yellow signals) and ALK -rearranged
copy. Arrows show the ALK rearrangement with a split 3′ and 5′
(red/green) signal. Scale bar: 8µm.
are most commonly identified on tumor biopsy samples although
tissue adequacy, both in terms of quantity and quality, is often
insufficient for patients with advanced/metastatic NSCLC. The
detection of an ALK rearrangement is currently performed on
small biopsies or fine-needle aspirates of the tumor but is hin-
dered by the very limited tissue quantities available. The diag-
nosis of ALK rearrangement can be performed by fluorescence
in situ hybridization (FISH, which is considered as the gold stan-
dard), immunohistochemistry (IHC), or reverse transcriptase-
polymerase chain reaction (RT-PCR) on these tumor samples.
Wang et al. recently reported that FISH and IHC results were con-
cordant in 98% of cases while RT-PCR results were less concordant
with FISH (89%). FISH is highly specific but is costly and requires
technical expertise. The IHC assay developed by Ventana (Ventana
Frontiers in Oncology | Thoracic Oncology November 2014 | Volume 4 | Article 281 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Faugeroux et al. CTCs’ utility in ALK -positive NSCLC
ALK assay) enables to detect ALK rearrangement with a high sen-
sitivity and concordance when compared to FISH results, and has
the advantage to be automated, faster, and less expensive than
FISH (13). Treatment with crizotinib was FDA approved with a
companion diagnostic test, the Vysis ALK break apart FISH probe
kit (Abott molecular). Finding alternatives to a tumor biopsy and
Table 1 | Numbers and percentages of ALK-rearranged cells in tumor and in CTCs of ALK-positive and ALK-negative patients.
ALK positive (P) or
negative (PN) patientsa
Sex Age Smoking statusb Tumor % of
rearranged cellsc
CTCs characterized by ISET
Total CTCs
(/mL)d
Rearranged
CTCs (/1mL)
% of
rearranged CTCse
P1 M 32 3 97% 16 9 56%
P2 M 35 0 47% 17 9 53%
P3 F 40 0 30% 10 5 50%
P4 M 54 0 30% 9 4 44%
P5 F 79 0 60% 25 10 40%
P6 F 69 0 43% 28g 34 100%
P7 M 69 20 27% 25 7 28%
P8 M 48 3.5 RT-PCR+f 25 24 96%
P9 F 70 40 61% 15 6 40%
P10 M 53 0 30% 17 7 41%
P11 F 25 0 68% 16 7 44%
P12 F 44 12.5 29% 10 9 90%
P13 F 36 0 77% 7 4 57%
P14 M 48 5 62% 17 11 65%
P15 F 42 0 25% 10 7 70%
P16 F 52 0 26% 14 9 64%
P17 F 42 10 25% 10g 11 100%
P18 F 57 0 28% 18g 25 100%
PN1 F 42 0 0% 45 0 0%
PN2 M 60 60 0% 26 0 0%
PN3 M 67 35 0% 4 1 0%
PN4 F 57 35 NA 42 1 2%
PN5 M 76 52 NA 13 0 0%
PN6 F 53 20 IHC 20 1 5%
PN7 F 53 45 NA 33 1 3%
PN8 M 44 40 NA 37 0 0%
PN9 M 54 30 0% 20 1 5%
PN10 M 59 40 0% 19 1 5%
PN11 F 59 20 0% 10 1 10%
PN12 M 66 100 0% 23 1 4%
PN13 M 66 75 0% 12 1 8%
PN14 M 75 60 0% 16 1 6%
ALK, anaplastic lymphoma kinase; CTC, circulating tumor cell; FISH, fluorescence in situ hybridization; NA, not available; RT-PCR, reverse transcription polymerase
chain reaction.
aAll patients have metastatic disease.
bNumber of pack-years. All patients are former or never smokers (0: never smokers).
cPercentage of rearranged tumor cells determined by FISH in tumor samples.
dTotal numbers of CTCs per milliliter were calculated as the mean of CTCs identified by combining a four-color immunofluorescent staining with cytomorphological
examination in 3×1 mL of blood.
ePercentage of ALK-rearranged CTCs is the proportion of ALK-rearranged CTCs determined by FA-FISH among total numbers of CTCs determined in independent
experiments by combining a four-color immunofluorescent staining with cytomorphological examination.
fThe biopsy was negative by FISH but positive by RT-PCR.
gIn this three patients, numbers of ALK-rearranged CTCs were slightly greater to the number of total CTCs identified by phenotypic analysis. This difference is due to
the fact that numbers of CTCs may differ between each spot of the filter.
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more effective means to diagnose an ALK rearrangement is a crit-
ical issue in order to identify NSCLC patients who may benefit
from an ALK inhibitor treatment.
Molecular characterization of circulating tumor cells (CTCs)
may inform on the status of predictive biomarkers for drug sen-
sitivity and therapy selection. CTCs are, however, very rare events
occurring at rates, as low as one cell per 106 or 107 leukocytes.
Most methods of CTC detection rely on the combination of two
successive steps, an initial enrichment process followed by CTC
detection so as to increase the sensitivity of the assay (14). Numer-
ous technical efforts have been made to reliably detect and quantify
CTCs, although the development of a universal assay has proven
quite difficult. The major technical challenges for CTC detection
are due to the rarity of CTCs and their high degree of phenotypi-
cal and molecular heterogeneity. Using the CellSearch platform,
which is based on the detection of epithelial cells expressing
EpCAM, CTCs levels have been observed to be prognostic in var-
ious metastatic solid tumors including NSCLC and SCLC. Using
an enrichment technique based on blood filtration (ISET, isola-
tion by size epithelial tumor cells), the prognostic value of CTCs
was also reported in patients with resected NSCLC. We and others
groups have reported that CTCs are identified in higher numbers
using the ISET technique compared to the CellSearch method in
NSCLC most likely due to the fact that CTCs expressing mark-
ers of epithelial–mesenchymal transition (EMT) and that have
lost epithelial features are missed by CellSearch (15). In spite of
technical difficulties, a few studies have demonstrated the feasibil-
ity of CTC assays for predictive biomarker detection. Two groups
including our own have reported the feasibility of detecting ALK
rearrangement from CTCs enriched by filtration in patients with
ALK -positive NSCLC (16, 17). Ilie et al. reported the detection
of ALK rearrangement and strong ALK protein expression by
IHC in CTCs from five patients with ALK -rearranged NSCLC.
FISH and IHC were negative in CTCs from 82 NSCLC patients
whose tumors did not harbor ALK rearrangement. In order to
exploit CTCs as predictive biomarkers of personalized treatments,
our group developed a FISH method on filters (filter adapted-
FISH, FA-FISH) that was optimized for high cell recovery. By
combining blood filtration and FA-FISH, we demonstrated that
ALK -rearranged CTCs could be detected in a cohort of 18 ALK -
positive NSCLC patients (17). All 18 ALK -positive patients had
four or more ALK -rearranged CTCs per milliliter of blood while
no or only one ALK -rearranged CTC was detected in 14 ALK -
negative patients (Table 1). Furthermore, all CTCs harbored a
unique ALK-rearrangement pattern consisting in the 3′5′ break
apart of ALK probes whereas heterogeneous rearrangement pat-
terns were present within the tumor. This unique 3′5′ pattern
was present in CTCs harboring either a single copy of ALK or
a gain of native ALK copies (Figure 1C). CTCs harboring an
isolated red signal pattern were never detected in ALK-positive
patients, even when isolated red signals were exclusively present in
the tumor biopsies. The split rearrangement pattern was therefore
detected in CTCs regardless of the frequency of tumor cells har-
boring this rearrangement in the tumor tissue. ALK -rearranged
CTCs harboring this unique rearrangement expressed a mesenchy-
mal phenotype, suggesting that these cells may have derived from
the clonal selection of tumor cells harboring greater invasive and
migratory properties (Figure 1D). In this study, we also demon-
strated that monitoring quantitative and qualitative changes of
CTCs with distinct ALK abnormalities pattern was feasible in
patients undergoing ALK inhibitor therapy.
By demonstrating that ALK rearrangement can be reliably
detected in the CTCs of ALK -positive NSCLC patients, these
two studies provide new perspectives for the diagnosis of ALK -
positive patients eligible for treatment with ALK inhibitors. These
non-invasive molecular analyses performed on CTCs could be eas-
ily repeated at different time-points during treatment and could
help to guide therapeutic decisions in a patient’s treatment course.
Single cell analyses of CTCs captured on filters at the time of dis-
ease progression are also anticipated to help characterize resistant
subclones and mechanisms of resistance to ALK inhibitors.
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